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Kinetic limitations of cooperativity based drug delivery systems
Nicholas A. Licata and Alexei V. Tkachenko
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We study theoretically a novel drug delivery system that utilizes the overexpression of certain
proteins in cancerous cells for cell specific chemotherapy. The system consists of dendrimers con-
jugated with ”keys” (ex: folic acid) which ”key-lock” bind to particular cell membrane proteins
(ex: folate receptor). The increased concentration of ”locks” on the surface leads to a longer res-
idence time for the dendrimer and greater incorporation into the cell. Cooperative binding of the
nanocomplexes leads to an enhancement of cell specificity. However, both our theory and detailed
analysis of in-vitro experiments indicate that the degree of cooperativity is kinetically limited. We
demonstrate that cooperativity and hence the specificity to particular cell type can be increased by
making the strength of individual bonds weaker, and suggest a particular implementation of this
idea. The implications of the work for optimizing the design of drug delivery vehicles are discussed.
Nanoparticle based drug delivery systems have at-
tracted substantial attention for their potential appli-
cations in cancer treatment ([1],[2],[3],[4],[5]). It is
hoped that by selectively targeting cancer cells with
chemotherapeutic agents one can reduce side effects and
improve treatment outcomes relative to other drug de-
livery systems which do not discriminate between nor-
mal and cancerous cells. For example, many epithe-
lial cancer cells are known to overexpress the folate
receptor([6],[7],[8],[9],[10]). A nanoparticle with many
folic acid ligands will preferentially bind to cancerous
cells. A recent study[11] of a potential drug delivery
platform consisting of generation 5 PAMAM dendrimers
with different numbers of folic acid found that multiva-
lent interactions have a pronounced effect on the dissoci-
ation constant KD. This enhancement is the signature
for cooperativity of the binding, which should lead to a
greater specificity to cancerous cells in vivo.
In this letter we present a theoretical study of these
key-locking nanodevices (see Fig. 1). We introduce the
idea that there are kinetic limitations to cooperativity-
based drug delivery systems. In vivo the finite timescale
for endocytosis prevents arbitrarily high cooperativity in
the drug delivery system. In the first part we provide
a detailed analysis of the in vitro experiments[11]. Al-
though enhancement of the association is the signature of
greater cooperativity, in this case it is due mostly to non-
specific binding of the dendrimers to the surface. Due
to the finite time window of the experiments, only in-
direct support can be offered to the notion of enhanced
cooperativity. In the second part we expand the notion
of kinetically limited cooperativity to the system in vivo.
The equilibrium coverage of nanodevices on the cells is re-
lated to the concentration of folate-binding proteins and
the strength of the key-lock binding. We quantify the
preferential adsorption of nanodevices to the cancerous
cells, and discuss how kinetic effects prohibit arbitrar-
ily high cooperativity in the drug delivery system. The
implications of the work for designing new drug delivery
vehicles with enhanced specificity to cancerous cells are
FIG. 1: (Color online). A picture of the dendrimer ”key-lock”
binding to the cell membrane surface.
discussed.
We now consider a simple model of the nanodevice sys-
tem. A dendrimer with a maximum ofM keys (e.g. folic
acids) interacts with locks (e.g. folate-binding proteins)
in the cell membrane surface. A simple order of magni-
tude estimate for M ≃ 30 can be obtained from the ratio
of the surface area of the dendrimer to the surface area of
the folic acid. In this way we implicitly take into account
the excluded volume effect between the keys. The free
energy for the dendrimer connected to the surface by m
key-lock bridges is[12]
Fm = −kBTm∆. (1)
The dimensionless energy parameter ∆ contains informa-
tion about the binding energy of a single key-lock pair,
and the entropy loss associated with localizing a den-
drimer on the cell-membrane surface. An estimate of
∆ ≃ 17.5 can be obtained from the dissociation con-
stant of free folic acid K
(o)
D using the equilibrium rela-
tion between the dissociation constant and the free en-
ergy change for the formation of a single key-lock bridge,
K
(o)
D =
1
ξ3
exp(−∆). Here ξ3 is the localization volume
of an ”unbound” key. Below we determine the value
2ξ ≃ 0.2nm from analysis of the in vitro experiments,
which was used to determine ∆.
The measured association rate constant ka of the den-
drimer with folic acid is a factor of 103 times greater
than k
(o)
a of free folic acid. Only a factor of m can
be attributed to the dendrimer having many folic acids
attached to it. Here m is the average number of keys at-
tached to the dendrimer. This pronounced enhancement
of ka is the primary evidence for non-specific attraction
between the dendrimer and the surface.
ka = mk
(o)
a exp
(
−ǫ0
kBT
)
(2)
The non specific attraction ǫ0 accounts for the Van der
Waals attraction to the surface and hydrophobic en-
hancement. The experimentally measured ka values are
reproduced by a reasonable energy scale −ǫ0 ≃ 7kBT
(see Fig. 2).
We provide a simple explanation for the experimen-
tally observed dependence of the dissociation rate con-
stant kd on m. The dissociation rate constant of free
folic acid k
(o)
d ∼ 10
−5
[
s−1
]
provides a characteristic de-
parture time of 1/k
(o)
d ≃ 30 hours for those dendrimers
attached by a single key-lock bridge. Moreover, the de-
parture time for multiple bridge states increases exponen-
tially in ∆, for two bridges it is exp(∆)/k
(o)
d ≃ 10
9 hours.
Strictly speaking the relaxation is multiexponential, with
time constants for each bridge number. However, the ex-
perimental kd values are well fit by a single exponential.
On the timescale of the experiment, we will only see the
departure of dendrimers attached by a single bridge.
The experiment measures the departure rate of den-
drimers which are connected to the surface by a single
bridge, but are unable to form an additional connection.
Consider a dendrimer attached to the surface by one key-
lock bridge. If the dendrimer has a total of j keys, the
probability that none of the remaining j − 1 keys can
form bridges is (1−α)j−1. We now compute the proba-
bility α that a remaining key is available to form a bridge.
In the vicinity of the surface the dendrimer is a disclike
structure[13] with radius a ≃ 4.8nm. By rotation of
the dendrimer about the first bridge, a key located at
position ρ searches the annulus of area 2πρξ to find a
lock. The probability of encountering a lock in this re-
gion is 2πρξσo, where the surface density of the locks
σo ≃
16
100nm2 . By averaging over the key location we
obtain the final result
α =
1
a
∫ a
0
2πρξσodρ ≃ ξaσo. (3)
Assuming that during dendrimer preparation the attach-
ment of folic acid to the dendrimer is a Poisson process,
the probability of a dendrimer having exactly j keys is
Pj(m) = exp(−m)m
j/j!. The final result is obtained by
averaging the probability that no additional bridges can
104ka
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FIG. 2: (Color online). Top: Plot of the association rate
constant (Eq. 2) ka[M
−1s−1] versus m. Bottom: Plot of the
effective dissociation rate constant (Eq. 4) kd[s
−1] versus m.
In the fit k
(o)
d
= 10−5[s−1] and α = 0.15. The experimental
data points are taken from Figure 5 in [11].
form over this distribution. The factor of j counts the
number of ways to make the first connection.
kd = k
(o)
d
∞∑
j=1
(1 − α)j−1jPj(m)
∞∑
j=1
jPj(m)
= k
(o)
d exp(−αm) (4)
The formula predicts an exponential decay of the ef-
fective dissociation rate constant with the average num-
ber of folic acids on the dendrimer, which allows for a
quantitative comparison to the experiment (see Fig. 2).
Using α ≃ 0.15, we can determine the localization length
ξ ≃ 0.2nm for locks in the experiment from Eq. 3. This
estimate for ξ is physically reasonable, and comparable to
the bond length of the terminal group on the dendrimer.
Similar to the finite timescale of the experiments in
vitro[11], in vivo the endocytosis time provides kinetic
limitations to cooperative binding. In equilibrium the
concentration of dendrimers on the cell surface n is re-
lated to the concentration of dendrimers in solution csol
through the association constant KA = n/(σocsol). Al-
though it is tempting to use our in vitro results to define
the association constant as KA = ka/kd, this approach is
only valid provided there is a single rate for both associ-
ation and dissociation. Because the dendrimer can form
multiple bridges, there are many different rate constants.
We present a partition function method which accounts
for the multiple rate constants in the problem, and for
the possibility that in vivo there is surface diffusion of
locks.
To proceed we construct a vector s of length M , which
is a list of the possible sites folic acid can attach to the
3dendrimer. If a folic acid is present at site i we have
si = 1, and otherwise si = 0. The concentration of
dendrimers on the cell surface n is proportional to the
partition function of the system.
n =
csolξ
3
A
∞∑
m=1
∫
d2r1 · · · d
2
rm
m!
∑
i6=j 6=···6=p
si · · · sp (5)
×σ(r1) · · ·σ(rm) exp
[
m∆−
ǫ0 + εij···p(r1, · · · , rm)
kBT
]
Here σ(r) is the surface density of locks on the cell mem-
brane at position r, and A denotes the total area of
the cell membrane. The energy εij···p(r1, · · · , rm) that
appears in the Boltzmann weight is the elastic energy
penalty required to form multiple bridges. The point is
that in solution the dendrimer is roughly spherical, but
must flatten to a pancake like shape to form multiple
connections with the cell surface[13].
The ensemble averaging is performed by assuming
that during nanodevice preparation the attachment of
folic acid to the dendrimer is a Poisson process. In
this case 〈si〉 =
m
M
is given by the success probabil-
ity that a folic acid attaches to the dendrimer, and
the m point correlator 〈sisj · · · sp〉 =
(
m
M
)m
. In other
words, the probability of attachment of a given folic
acid to a terminal group on the dendrimer is unaffected
by the presence of other folic acids up to an exclu-
sion rule which has already been taken into account.
If the interaction potential between locks in the cell
membrane is V (r1, · · · , rm) we have 〈σ(r1) · · ·σ(rm)〉 =
(σo)
m exp [−V (r1, · · · , rm)/kBT ]. By performing the en-
semble averaging we arrive at the result for the equilib-
rium coverage neqm of dendrimers connected to the cell
surface by m bridges.
neqm =
csolξ
3
m!
(
mσo
M
)m
exp
[
m∆−
ǫ0
kBT
] ∑
i6=j 6=···6=p
×
∫
d2r2 · · · d
2
rm exp
[
−
(εij···p + V ) (0, r2, · · · , rm)
kBT
]
neqm =
csolξ
m!
(
mK
(o)
A σo
ξ
)m
exp

−
(
ǫ
(m)
el + ǫ0
)
kBT

 (6)
Here K
(o)
A = 1/K
(o)
D = ξ
3 exp(∆) is the association
constant of free folic acid which has been measured ex-
perimentally. Defined in this manner, exp(−ǫ
(m)
el /kBT )
has a physical interpretation as the Boltzmann weight
for the elastic energy of the optimal m bridge configura-
tion. The membrane surface can only accomodate a fi-
nite number of locks in the vicinity where the dendrimer
is attached[11]. As a result neqm = 0 for m > mmax
since forming additional key-lock pairs would require de-
forming the dendrimer into configurations prohibited by
elastic stress and steric hindrance. The calculation of
the equilibrium coverage above is applicable with and
without diffusion of locks in the cell membrane. In the
regime of fast diffusion the locks are free to diffusively ex-
plore the surface. Their positions are ergodic variables,
and the overall ensemble averaged equilibrium coverage
counts the Boltzmann weights for different lock configu-
rations. In the regime of slow diffusion, locks are im-
mobilized in the cell membrane. This is the relevant
situation when the locks have phase separated into pro-
tein rich (lipid rafts) and protein poor phases.
When kinetic effects are taken into account, these two
regimes are drastically different. When locks are diffus-
ing, the dendrimer is able to attain the maximum coop-
erativitymmax. After the dendrimer makes the first con-
nection, it simply waits for locks to diffuse in the vicinity
of available keys to make additional connections. In the
absence of diffusion, the optimal configuration can only
be obtained by multiple binding and unbinding events,
the timescale for which is prohibitively long. This is the
case for lipid rafts where the locks are immobilized sim-
ilar to the experiments in vitro[11], and the dendrimer
is unable to attain the maximum cooperativity. This
is the kinetic origin of limited cooperativity in the drug
delivery system.
We now quantify the preferential attachment of nan-
odevices to the cancerous cells, taking into account ki-
netic effects. Let nm denote the concentration of den-
drimers attached to the cell by m bridges. We can con-
struct a differential equation for nm by considering linear
response to the deviation from thermal equilibrium neqm .
dnm
dt
= k
(m)
d (n
eq
m − nm)− γnm (7)
Here γ is the rate for endocytosis[14]. The dissociation
rate constant k
(m)
d for breaking all m bridges is:
k
(m)
d = m
k
(o)
a
ξ3
exp
(
ǫ
(m)
el
kBT
)
exp(−m∆) (8)
The steady state concentration nssm is the solution to
dnm
dt
= 0. As a result we obtain the total coverage n
of dendrimers on the cell surface in the following form:
n =
mmax∑
m=1
nssm =
mmax∑
m=1
neqm
1 + γ/k
(m)
d
(9)
We now have a means to discuss the preferential at-
tachment of dendrimers to the cancerous cell. The folate
binding proteins on the cancerous cell are overexpressed,
i.e. if their concentration on the normal cell is σo, their
concentration on the cancerous cell is rσo with r > 1.
The value of r is determined by the biology, and cannot
be changed by the experimenter. To quantify the pref-
erential binding of the dendrimer to the cancerous cells
we calculate the ratio of coverage on cancerous to normal
cells n(rσo)
n(σo)
. Values of this ratio greater than r indicate
the nature of cooperative dendrimer binding (see Fig. 3).
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FIG. 3: (Color online). The ratio of surface concentrations of
dendrimers on cancerous to normal cells n(10σo)
n(σo)
as a function
of ∆ with r = 10. The dotted line corresponds to an endo-
cytosis time 1/γ = 1 [hr] and the solid line is 1/γ = 10 [hr].
Herem = 15, mmax = 4, ξ = 3[nm], and σo = 2×10
−3[nm−2].
ε
(m)
el
= 3kBT for m ≥ 3 bridges.
FIG. 4: (Color online). Single-stranded DNA (ssDNA) on
the dendrimer hybridize to the ssDNA attached to the folic
acid (FA) key.
The current experimental scheme uses direct targeting
with folic acid (∆FA ≃ 17.5), which does not optimize the
coverage on cancerous cells. By decreasing ∆ the drug
delivery can be tuned to the favorable regime. To do
so, consider binding to the cell through an intermediary,
perhaps single-stranded DNA (ssDNA). Instead of folic
acid, attach many identical sequences of ssDNA to the
dendrimer. Then, one also constructs a folic acid-ssDNA
complex with the ssDNA sequence complementary to
that of the ssDNA attached to the dendrimer. The folic
acid will bind very strongly to the folic acid receptors
on the cell membrane, leaving the unhybridized ssDNA
as a receptor (see Fig. 4). Effectively one has replaced
∆FA with a new value ∆DNA which can be tuned very
precisely by controlling the length and sequence of the
DNA. Due to the large degree of overexpression[6], this
change substantially increases the ratio of dendrimers on
cancerous to normal cells. As indicated in Fig. 3, with
r ≃ 10 there is a 5 fold improvement over direct targeting
with folic acid!
In this work we presented a theoretical study of a cell-
specific, targeted drug delivery system. A simple ”key-
lock” model was proposed to determine the effective dis-
sociation rate and association rate constants of the den-
drimers as a function of the average number of folic acids,
which permits a direct comparison to the experimental
results. The equilibrium coverage of dendrimers on the
cell surface was calculated, and the differences between
in vitro experiments and in vivo studies were discussed.
The degree of cooperativity of the drug delivery system
is kinetically limited. We quantified the notion of pref-
erential selection of dendrimers to cancerous cells, and
demonstrated that the selectivity can be enhanced by de-
creasing the strength of individual bonds. A particular
implementation of this idea using ssDNA was discussed.
This work was supported by the ACS Petroleum Re-
search Fund (PRF Grant No. 44181-AC10). We ac-
knowledge B. Orr, M. Holl, P. Leroueil, and C. Kelly for
valuable discussions.
[1] A. R. Hilgenbrink and P. S. Low, J. Pharm. Sci. 94, 2135
(2005).
[2] Y. J. Lu and P. S. Low, Adv. Drug Deliv. Rev. 54, 675
(2002).
[3] B. Stella, S. Arpicco, M. T. Peracchia, D. Desmaele,
J. Hoebeke, M. Renoir, J. D’Angelo, L. Cattel, and
P. Couvreur, J. Pharm. Sci. 89, 1452 (2000).
[4] A. Quintana, E. Raczka, L. Piehler, I. Lett, A. Myc,
I. Majoros, A. K. Patri, T. Thomas, J. Mule, and J. R. B.
Jr., Pharm. Res. 19, 1310 (2002).
[5] Y. Choi, A. Mecke, B. G. Orr, and J. R. B. Jr., Nanolet-
ters 4, 391 (2004).
[6] G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli,
and M. Boiocchi, Int. J. Cancer (Pred. Oncol.) 74, 193
(1997).
[7] J. F. Ross, P. K. Chaudhuri, and M. Ratnam, Cancer 73,
2432 (1994).
[8] S. D. Weitman, A. G. Weinberg, L. R. Coney, V. R.
Zurawski, D. S. Jennings, and B. A. Kamen, Cancer Res.
52, 6708 (1992).
[9] S. D. Weitman, R. H. Lark, L. R. Coney, D. W. Fort,
V. Frasca, V. R. Zurawski, and B. A. Kamen, Cancer
Res. 51, 3396 (1992).
[10] I. G. Campbell, T. A. Jones, W. D. Foulkes, and
J. Trowsdale, Cancer Res. 51, 5329 (1991).
[11] S. Hong, P. R. Leroueil, I. J. Majoros, B. G. Orr, J. R. B.
Jr., and M. M. B. Holl, Chemistry and Biology 14, 107
(2007).
[12] N. A. Licata and A. V. Tkachenko, Phys. Rev. E 74,
041408 (2006).
[13] A. Mecke, I. Lee, J. R. B. Jr., M. M. B. Holl, and B. G.
Orr, Eur. Phys. J. E 14, 7 (2004).
[14] R. Wiwattanapatapee, B. Carren˜o-Go´mez, N. Malik, and
R. Duncan, Pharmaceutical Research 17, 991 (2000).
